Google+ Followers [Join for FREE]

Friday, December 14, 2012

Medical Food Video Interview on The Balancing Act (TV)




Check out this vide on Medical Foods: 
 


12/14/12 The Future of Medical Foods - Nutraceuticals World

www.nutraceuticalsworld.com/contents/view_online-exclusives/2011-12-15/the-future-of-medical-foods/

The Future of Medical Foods
Metagenics conference stresses the importance of science as
the foundation of new therapeutic foods formulated to fight
against chronic illness and obesity.

By Joanna Cosgrove

Originally developed to use in the treatment of genetic metabolic diseases in infants, the evolution of medical
foods—products specially formulated to address specific health concerns—has gained steady momentum in
recent years, even earning formal recognition from FDA. The forerunner in the field, San Clemente, CA-based
Metagenics, Inc., delivered a series of workshop presentations on regulatory, research and business trends of
medical foods at the recent World Health Forum at Harvard Medical School. According to Metagenics’ Jeffrey
Bland, PhD, the company’s chief science officer and host of presentations, the future of food lies in the science
of nutrigenomics, the study of how food affects genetic expression at the cellular level.
“Medical foods taken with a low-glycemic Mediterranean diet have been tested and proven effective in reducing
metabolic syndrome, a condition that increases the likelihood of an individual developing heart disease, diabetes
and other lifestyle-related conditions,” noted Dr. Bland. “This discovery is a tremendous benefit to the healthcare
system. Now healthcare practitioners can expand their use of medical foods to help their patients to achieve
better health today, and for the rest of their lives.”
At Metagenics, Dr. Bland helms a team of more than 40 scientists in the field of nutrigenomics, where the
researchers test the phytonutrients found in plants for their health properties. Their work has earned more than
50 international and U.S. patents, and has been published in more than 80 peer-reviewed research journal
articles.
During his presentation, Willy PardiƱas, Metagenics’ senior vice president, general manager of Americas, spoke
about how scientific validation is the foundation for the acceptance and widespread use of promising medical
foods. “The companies that are succeeding with medical foods are those that demonstrate a commitment to real
science and evidence-based medicine,” he said. “They use the highest standards of clinical research including
the double-blind, placebo controlled studies. Now, traditional pharmaceutical companies are beginning to see the
value of medical foods as part of their portfolio, when these products bring clinical proof and broad applicability for
fighting chronic illness.”
J.D. Weir, president and CEO of Primus Pharmaceuticals, echoed Mr. PardiƱas’ sentiments on the principles of
solid science. “If we’re serious about giving healthcare practitioners real solutions for combating chronic disease,
they need to know our solutions work and can deliver predictable outcomes,” he said.
An estimated one-third of Americans currently have metabolic syndrome. Most of those afflicted with this
condition aren’t even aware they have it, or that it is putting them at greater risk of developing a chronic illness.
According to Metagenics, helping patients to reverse metabolic syndrome will significantly lower the number of
individuals who develop heart disease and diabetes, which in turn will fight the rapidly growing epidemic of these
ailments that is occurring around the world.
Robert Lerman, MD, PhD, medical director for Metagenics, moderated a session on the clinical application of
medical foods and cited research published earlier this year in the Journal of Clinical Lipidology on the effect of a
medical food in helping reverse metabolic syndrome. The article reported the findings of a 12-week multi-center
clinical trial conducted at three universities that showed Metagenics’ UltraMeal PLUS 360° medical food and a
low-glycemic Mediterranean diet is almost twice as likely to lower certain cardiovascular risk factors as this
same diet alone, and is 40% more likely to resolve the effects of metabolic syndrome.
Deanna Minich, PhD, Metagenics’ vice president of scientific affairs, addressed the importance of phytonutrients
in the medical food delivery form, while Matthew Tripp, PhD, vice president, research & development, spoke
about the breadth of active ingredients in medical foods that have an impact on chronic disease.
Next Generation Multi
In separate but related news, Metagenics recently announced the launch of a “professional brand” daily
supplement that was formulated in adherence to the same clinical standards as its aforementioned UltraMeal
PLUS 360° medical food.
According to the company, PhytoMulti is positioned as a “Smart Multi” daily supplement designed to “activate
health potential with a science-based combination of phytonutrients, vitamins, and minerals,” targeting “cellular
health to nourish cells, recharge cellular communication, and defend against free radical damage.
Metagenics said PhytoMulti was created using extensive research to develop a strategic combination of
phytonutrients—bioactive secondary metabolites in plant-based foods—known for their antioxidant properties and
“positive influence on cell signaling to communicate healthy messages throughout the body.” The proprietary
formulation of 13 concentrated plant extracts and phytonutrients (resveratrol, lutein, zeaxanthin and lycopene, as
well as an “optimized” blend of essential minerals and vitamins, including vitamin D3, folate and B12) was
scientifically tested for potential biological activity to protect cells via antioxidant capacity and maintenance of
DNA stability.
An independent laboratory evaluated PhytoMulti’s proprietary blend and the entire combination of
ingredients with the new total functional oxygen radical absorbance capacity (ORAC FN) assay that measures
against five major free radicals. Unlike a conventional ORAC, which tests against only one radical, this expanded
in vitro assay was said to have provided “a better sense of antioxidant protection against a variety of potentially
damaging free radicals and other reactive oxygen species.” The analysis of PhytoMulti’s active ingredients
(equivalent to the contents in one tablet) returned a total ORAC FN value of 12,600 trolox, demonstrating
“exceptional” antioxidant capacity.
Metagenics also said the potential of the phytonutrient blend to help maintain DNA stability was validated using
the COMET assay, a complex in vitro test using human immune cells. This assay demonstrated a 52% increase
in DNA stability when cells pretreated with the phytonutrient blend were compared to control cells introduced to
the same oxidative medium (peroxides).
PhytoMulti will be available January 1, 2012, through health practitioners nationwide. PhytoMulti with Iron,
formulated for those who need supplemental iron, will be available February 1, 2012.



Thursday, December 13, 2012

Statins and Breast Cancer Risk

Logo

Studies put kibosh on statins for breast cancer prevention


12/10/12

Bookmark and Share  | 
SAN ANTONIO – New data from the Women’s Health Initiative dash cold water on the idea that statin therapy reduces breast cancer risk.
The updated WHI findings showed no association between prior statin use and breast cancer risk in nearly 155,000 postmenopausal study participants followed prospectively for an average of 10.8 years.
Indeed, the annualized rate of breast cancer was 0.42% in 11,584 statin users and 0.42% in nonusers in this analysis of 7,430 first cases of invasive breast cancer, Dr. Pinkal Desai reported at the San Antonio Breast Cancer Symposium.
Statin potency, duration of use, lipophilicity versus hydrophilicity – none of those factors had any impact, added Dr. Desai of Providence Hospital Medical Center in Southfield, Mich.
In commenting on Dr. Desai’s WHI update at a session on statins and breast cancer risk, Dr. Vered Stearns noted that the new data represent quite a turnabout, since an earlier report from the WHI was one of the major initial triggers of interest in the notion that statins might protect against breast cancer.
That report (J. Natl. Cancer Inst. 2006;98:700-7) analyzed 4,383 cases of invasive breast cancer among study participants followed for a median of 6.7 years. It showed no reduction in breast cancer risk in association with statins overall; however, there was an 18% reduction in risk (P = .02) among users of lipophilic statins, including simvastatin, lovastatin, and fluvastatin. With longer follow-up and more cases, however, that earlier benefit is gone, observed Dr. Stearns of Johns Hopkins University, Baltimore.
Moreover, a new meta-analysis has put a further damper on the hypothesis that statins protect against breast cancer, she continued. The meta-analysis included 13 published cohort and 11 case-control studies with more than 2.4 million participants, including 76,759 breast cancer patients. The investigators, from the National Institute of Pharmaceutical Education and Research in Punjab, India, found that neither statin use overall nor long-term statin therapy affected breast cancer risk (Breast Cancer Res. Treat. 2012;135:261-9).
Dr. Desai noted that the latest WHI findings do contain one glimmer of hope regarding statins and breast cancer: In a multivariate analysis, women on simvastatin were 13% less likely to develop breast cancer than statin nonusers after adjustment for demographic factors, body mass index, smoking, alcohol intake, family history, age at menarche and at first birth, NSAID use, dietary fat, physical activity, and mammography within the past 2 years. However, this trend toward reduced breast cancer risk with simvastatin therapy didn’t achieve statistical significance.
Statins are safe and cheap, and multiple products are readily available. But in light of the discouraging new epidemiologic data, Dr. Stearns declared "I think that the effects of statins as single agents are modest at best. There’s quite a good rationale, though, for prospective studies of them in combination with standard hormonal therapy, chemotherapy, and radiation therapy, as well as with novel cancer treatment agents."
She added that the statins remain worthy of research interest because many of their pleomorphic cellular effects are antineoplastic. The drugs inhibit the mevalonate pathway, down-regulate metalloproteinases, inhibit Rho and Ras activation, decrease CD44 cells, and increase PTEN antibodies, all of which are salutary from an anticarcinogenesis standpoint.
Dr. Desai and Dr. Stearns reported having no financial conflicts of interest.


Copyright © 2012 International Medical News Group, LLC. All rights reserved. 
This page was printed from www.familypracticenews.com . For reprint inquires, call 877-652-5295, ext. 102.

About Me

My photo
Charleston; Myrtle Beach, SC; Raleigh-Durham, NC; Orlando, FL, GA, NC, SC, VA, FL, United States
http://www.PHC365.com http://www.CarolinaHolisticMedicine.com http://www.CentralFloridaHolisticMedicine.com